Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 0420510 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1768-3254 (Electronic) Linking ISSN: 02235234 NLM ISO Abbreviation: Eur J Med Chem Subsets: MEDLINE
    • Publication Information:
      Publication: Paris : Editions Scientifiques Elsevier
      Original Publication: Paris, S.E.C.T. [etc.]
    • Subject Terms:
      Multiple Myeloma*/drug therapy ; Multiple Myeloma*/pathology ; Drug Resistance, Neoplasm*/drug effects ; Antineoplastic Agents*/pharmacology ; Antineoplastic Agents*/chemistry ; Antineoplastic Agents*/therapeutic use ; Small Molecule Libraries*/chemistry ; Small Molecule Libraries*/pharmacology; Humans ; Proteasome Inhibitors/pharmacology ; Proteasome Inhibitors/chemistry ; Proteasome Inhibitors/therapeutic use ; Molecular Structure
    • Abstract:
      Multiple myeloma (MM), a cancer of plasma cells, is the second most common hematological malignancy which is characterized by aberrant plasma cells infiltration in the bone marrow and complex heterogeneous cytogenetic abnormalities. Over the past two decades, novel treatment strategies such as proteasome inhibitors, immunomodulators, and monoclonal antibodies have significantly improved the relative survival rate of MM patients. However, the development of drug resistance results in the majority of MM patients suffering from relapse, limited treatment options and uncontrolled disease progression after relapse. There are urgent needs to develop and explore novel MM treatment strategies to overcome drug resistance and improve efficacy. Here, we review the recent small molecule therapeutic strategies for MM, and introduce potential new targets and corresponding modulators in detail. In addition, this paper also summarizes the progress of multi-target inhibitor therapy and protein degradation technology in the treatment of MM.
      Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
      (Copyright © 2024 Elsevier Masson SAS. All rights reserved.)
    • Contributed Indexing:
      Keywords: Drug resistance; Multiple myeloma; Potential targets; Small molecule; Structure-activity relationships
    • Accession Number:
      0 (Antineoplastic Agents)
      0 (Small Molecule Libraries)
      0 (Proteasome Inhibitors)
    • Publication Date:
      Date Created: 20240422 Date Completed: 20240511 Latest Revision: 20240515
    • Publication Date:
      20240515
    • Accession Number:
      10.1016/j.ejmech.2024.116435
    • Accession Number:
      38648728